These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15983905)

  • 1. A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature.
    Robertson SM; Penzak SR; Lane J; Pau AK; Mican JM
    Clin Infect Dis; 2005 Jul; 41(2):e15-8. PubMed ID: 15983905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical interaction between efavirenz and phenytoin.
    Spak CW; Dhanireddy S; Kosel BW
    AIDS; 2008 Jan; 22(1):164-5. PubMed ID: 18090412
    [No Abstract]   [Full Text] [Related]  

  • 3. Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations.
    Goicoechea M; Best B; Capparelli E; Haubrich R;
    Clin Infect Dis; 2006 Jul; 43(1):116-7. PubMed ID: 16758435
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
    Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
    Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient.
    Saraga M; Preisig M; Zullino DF
    Bipolar Disord; 2006 Aug; 8(4):415-7. PubMed ID: 16879143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
    Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
    J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
    Mathiesen S; Justesen US; Von Lüttichau HR; Hansen AB
    Scand J Infect Dis; 2006; 38(8):733-5. PubMed ID: 16857630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.
    Motsinger AA; Ritchie MD; Shafer RW; Robbins GK; Morse GD; Labbe L; Wilkinson GR; Clifford DB; D'Aquila RT; Johnson VA; Pollard RB; Merigan TC; Hirsch MS; Donahue JP; Kim RB; Haas DW
    Pharmacogenet Genomics; 2006 Nov; 16(11):837-45. PubMed ID: 17047492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
    Tsuchiya K; Gatanaga H; Tachikawa N; Teruya K; Kikuchi Y; Yoshino M; Kuwahara T; Shirasaka T; Kimura S; Oka S
    Biochem Biophys Res Commun; 2004 Jul; 319(4):1322-6. PubMed ID: 15194512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical history of efavirenz.
    Ruiz N
    Int J Clin Pract Suppl; 1999 Jun; 103():3-7. PubMed ID: 10622035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G; Khoo S; Jack C; Lalloo U
    J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
    Haas DW; Smeaton LM; Shafer RW; Robbins GK; Morse GD; Labbe L; Wilkinson GR; Clifford DB; D'Aquila RT; De Gruttola V; Pollard RB; Merigan TC; Hirsch MS; George AL; Donahue JP; Kim RB
    J Infect Dis; 2005 Dec; 192(11):1931-42. PubMed ID: 16267764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential drug-herbal interaction between Ginkgo biloba and efavirenz.
    Naccarato M; Yoong D; Gough K
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):98-100. PubMed ID: 22323244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ACTG-study 5095: superiority of efavirenz containing drug scheme].
    Dtsch Med Wochenschr; 2003 May; 128(19):1076. PubMed ID: 12774799
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
    J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature.
    Torno MS; Witt MD; Saitoh A; Fletcher CV
    Pharmacotherapy; 2008 Jun; 28(6):782-7. PubMed ID: 18503405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
    Burger D; van der Heiden I; la Porte C; van der Ende M; Groeneveld P; Richter C; Koopmans P; Kroon F; Sprenger H; Lindemans J; Schenk P; van Schaik R
    Br J Clin Pharmacol; 2006 Feb; 61(2):148-54. PubMed ID: 16433869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.